MYC proto-oncogene, bHLH transcription factor | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | MYC | ||||||
Alt. symbols | c-Myc, v-myc | ||||||
NCBI gene | 4609 | ||||||
HGNC | 7553 | ||||||
OMIM | 190080 | ||||||
RefSeq | NM_001354870.1 | ||||||
UniProt | P01106 | ||||||
Other data | |||||||
Locus | Chr. 8 q24.21 | ||||||
Wikidata | Q20969939 | ||||||
|
MYCL proto-oncogene, bHLH transcription factor | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | MYCL | ||||||
Alt. symbols | LMYC, MYCL1, bHLHe38, L-Myc, v-myc | ||||||
NCBI gene | 4610 | ||||||
HGNC | 7555 | ||||||
OMIM | 164850 | ||||||
RefSeq | NM_005376 | ||||||
UniProt | P12524 | ||||||
Other data | |||||||
Locus | Chr. 1 p34.2 | ||||||
Wikidata | Q18029714 | ||||||
|
MYCN proto-oncogene, bHLH transcription factor | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | MYCN | ||||||
NCBI gene | 4613 | ||||||
HGNC | 7559 | ||||||
OMIM | 164840 | ||||||
RefSeq | NM_005378 | ||||||
UniProt | V | ||||||
Other data | |||||||
Locus | Chr. 2 p24.3 | ||||||
Wikidata | Q14906753 | ||||||
|
Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc (also sometimes referred to as MYC) was the first gene to be discovered in this family, due to homology with the viral gene v-myc.
In cancer, c-myc is often constitutively (persistently) expressed. This leads to the increased expression of many genes, some of which are involved in cell proliferation, contributing to the formation of cancer.[1] A common human translocation involving c-myc is critical to the development of most cases of Burkitt lymphoma.[2] Constitutive upregulation of Myc genes have also been observed in carcinoma of the cervix, colon, breast, lung and stomach.[1]
Myc is thus viewed as a promising target for anti-cancer drugs.[3] Unfortunately, Myc possesses several features that have rendered it difficult to drug to date, such that any anti-cancer drugs aimed at inhibiting Myc may continue to require perturbing the protein indirectly, such as by targeting the mRNA for the protein rather than via a small molecule that targets the protein itself.[4][5]
c-Myc also plays an important role in stem cell biology and was one of the original Yamanaka factors used to reprogram somatic cells into induced pluripotent stem cells.[6]
In the human genome, C-myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes[7] through binding on enhancer box sequences (E-boxes).
In addition to its role as a classical transcription factor, N-myc may recruit histone acetyltransferases (HATs). This allows it to regulate global chromatin structure via histone acetylation.[8]